Elizabeth H.Z. Thompson Sells 16,558 Shares of ACADIA Pharmaceuticals (NASDAQ:ACAD) Stock

Posted by on Aug 2nd, 2026

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD – Get Free Report) EVP Elizabeth H.Z. Thompson sold 16,558 shares of ACADIA Pharmaceuticals stock in a transaction dated Thursday, July 30th. The stock was sold at an average price of $26.13, for a total value of $432,660.54. Following the completion of the transaction, the executive vice president directly owned 18,994 shares of the company’s stock, valued at approximately $496,313.22. This represents a 46.57% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.

ACADIA Pharmaceuticals Stock Performance

Shares of ACAD stock opened at $25.87 on Friday. ACADIA Pharmaceuticals Inc. has a one year low of $19.69 and a one year high of $28.35. The company’s 50-day moving average is $23.74 and its 200 day moving average is $23.23. The company has a market capitalization of $4.43 billion, a price-to-earnings ratio of 11.76, a price-to-earnings-growth ratio of 17.94 and a beta of 0.80.

ACADIA Pharmaceuticals (NASDAQ:ACAD – Get Free Report) last released its quarterly earnings data on Wednesday, May 6th. The biopharmaceutical company reported $0.02 earnings per share for the quarter, missing analysts’ consensus estimates of $0.04 by ($0.02). The firm had revenue of $268.10 million for the quarter, compared to the consensus estimate of $280.25 million. ACADIA Pharmaceuticals had a net margin of 34.30% and a return on equity of 9.61%. The firm’s revenue for the quarter was up 9.7% compared to the same quarter last year. During the same quarter in the prior year, the business posted $0.11 earnings per share. As a group, research analysts predict that ACADIA Pharmaceuticals Inc. will post 0.39 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of brokerages recently weighed in on ACAD. Canaccord Genuity Group boosted their price objective on shares of ACADIA Pharmaceuticals from $32.00 to $36.00 and gave the stock a “buy” rating in a report on Monday, June 29th. Deutsche Bank Aktiengesellschaft reiterated a “buy” rating and set a $37.00 target price on shares of ACADIA Pharmaceuticals in a research note on Monday, June 29th. Weiss Ratings reissued a “hold (c)” rating on shares of ACADIA Pharmaceuticals in a report on Wednesday. Royal Bank Of Canada boosted their price target on ACADIA Pharmaceuticals from $29.00 to $36.00 and gave the stock an “outperform” rating in a research note on Tuesday, July 7th. Finally, Stifel Nicolaus upped their price target on ACADIA Pharmaceuticals from $24.00 to $25.00 and gave the company a “hold” rating in a report on Tuesday, July 21st. Thirteen research analysts have rated the stock with a Buy rating, four have given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, ACADIA Pharmaceuticals presently has an average rating of “Moderate Buy” and an average price target of $32.31.

Read Our Latest Analysis on ACAD

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the stock. State Street Corp boosted its holdings in ACADIA Pharmaceuticals by 9.0% in the fourth quarter. State Street Corp now owns 7,910,733 shares of the biopharmaceutical company’s stock worth $211,296,000 after purchasing an additional 655,257 shares during the last quarter. First Trust Advisors LP raised its stake in ACADIA Pharmaceuticals by 47.3% during the 1st quarter. First Trust Advisors LP now owns 3,343,868 shares of the biopharmaceutical company’s stock valued at $74,435,000 after buying an additional 1,073,834 shares during the last quarter. Geode Capital Management LLC raised its stake in ACADIA Pharmaceuticals by 3.4% during the 4th quarter. Geode Capital Management LLC now owns 3,239,451 shares of the biopharmaceutical company’s stock valued at $86,539,000 after buying an additional 106,807 shares during the last quarter. Dimensional Fund Advisors LP raised its stake in ACADIA Pharmaceuticals by 8.0% during the 1st quarter. Dimensional Fund Advisors LP now owns 3,155,160 shares of the biopharmaceutical company’s stock valued at $70,222,000 after buying an additional 234,186 shares during the last quarter. Finally, Marshall Wace LLP lifted its holdings in shares of ACADIA Pharmaceuticals by 19.8% during the 3rd quarter. Marshall Wace LLP now owns 2,358,881 shares of the biopharmaceutical company’s stock valued at $50,339,000 after buying an additional 389,170 shares during the period. 96.71% of the stock is owned by hedge funds and other institutional investors.

ACADIA Pharmaceuticals Company Profile

(Get Free Report)

ACADIA Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of innovative therapies for central nervous system (CNS) disorders. Established in 1993 and headquartered in San Diego, California, ACADIA’s research centers concentrate on conditions with significant unmet medical needs, including Parkinson’s disease psychosis, Alzheimer’s disease psychosis, and schizophrenia. The company utilizes a range of scientific platforms, including selective receptor modulation and precision-targeted compounds, to advance its portfolio of small-molecule therapeutics.

The company’s flagship product, NUPLAZID® (pimavanserin), received U.S.

Featured Articles

Insider Buying and Selling by Quarter for ACADIA Pharmaceuticals (NASDAQ:ACAD)

Receive News & Ratings for ACADIA Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ACADIA Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.